Circulating tumor cells in patients with castration-resistant prostate cancer baseline values and correlation with prognostic factors

Cancer Epidemiology Biomarkers and Prevention

Volumn 18, Issue 6, 2009, Pages 1904-1913

  Goodman Jr , Oscar B ^a   Fink, Louis M ^a   Symanowski, James T ^a   Wong, Bryan ^a   Grobaski, Beth ^a   Pomerantz, David ^a   Ma, Yupo ^a   Ward, David C ^a   Vogelzang, Nicholas J ^a  

^a NEVADA CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LACTATE DEHYDROGENASE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CASTRATION; CELL COUNT; CIRCULATING TUMOR CELL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; SENSITIVITY AND SPECIFICITY; TUMOR CELL;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; DRUG RESISTANCE, NEOPLASM; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; NEOPLASTIC CELLS, CIRCULATING; PROGNOSIS; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 67449107298     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-08-1173     Document Type: Article

References (23)

1. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence-SEER 9 Regs Limited-Use, Nov 2007 Sub (1973-2005) 〈Katrina/Rita Population Adjustment〉-Linked To County Attributes-Total U S., 1969-2005 Counties, National Cancer Institute DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2008, based on the November 2007 submission.
2. Halabi S, Vogelzang NJ, Ou SS, Kelly WK, Small EJ. Clinical outcomes by age in men with hormone refractory prostate cancer: a pooled analysis of 8 Cancer and Leukemia Group B (CALGB) studies. J Urol 2006;176:81-86 (Pubitemid 43815397)
3. Petrylak DP, Ankerst DP, Jiang CS, et al. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst 2006;98:516-521 (Pubitemid 43898814)
4. Miller PD, Eardley I, Kirby RS. Prostate specific antigen and bone scan correlation in the staging and monitoring of patients with prostatic cancer. Br J Urol 1992;70:295-298
5. Figg WD, Ammerman K, Patronas N, et al. Lack of correlation between prostate-specific antigen and the presence of measurable soft tissue metastases in hormone-refractory prostate cancer. Cancer Invest 1996;14:513-517 (Pubitemid 26423513)
6. Moreno JG, Croce CM, Fischer R, et al. Detection of hematogenous micrometastasis in patients with prostate cancer. Cancer Res 1992;52:6110-6112
7. Olsson CA, De Vries GM, Benson MC, et al. The use of RT-PCR for prostate-specific antigen assay to predict potential surgical failures before radical prostatectomy: molecular staging of prostate cancer. Br J Urol 1996;77:411-417 (Pubitemid 26090975)
8. Kantoff PW, Halabi S, Farmer DA, Hayes DF, Vogelzang NA, Small EJ. Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in men with hormone-refractory prostate cancer. J Clin Oncol 2001;19:3025-3028 (Pubitemid 32565439)
9. Halabi S, Small EJ, Hayes DF, Vogelzang NJ, Kantoff PW. Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in metastatic prostate cancer: a nested study within CALGB 9583. J Clin Oncol 2003;21:490-495 (Pubitemid 46606479)
10. Vidaurreta M, Sastre J, Sanz-Casla MT, Maestro ML, Rafael S, Diaz-Rubio E. Detection and quantification of circulating tumor cells in peripheral blood in patients with colon cancer. Med Clin (Barc) 2007;129:333-334 (Pubitemid 47581555)
11. Cristofanilli M, Budd GT, Ellis MJ, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004;351:781-791 (Pubitemid 39095313)
12. Cristofanilli M, Hayes DF, Budd GT, et al. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol 2005;23:1420-1430 (Pubitemid 46260029)
13. Budd GT, Cristofanilli M, Ellis MJ, et al. Circulating tumor cells versus imaging-predicting overall survival in metastatic breast cancer. Clin Cancer Res 2006;12:6403-6409 (Pubitemid 44799711)
14. Allard WJ, Matera J, Miller MC, et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 2004;10:6897-6904 (Pubitemid 39383039)
15. Sastre J, Maestro ML, Puente J, et al. Circulating tumor cells in colorectal cancer: correlation with clinical and pathological variables. Ann Oncol 2008;19:935-938 (Pubitemid 351627310)
16. Veridex L. CellSearch Circulating Tumor Cell Kit premarket notification-expanded indications for use-colorectal. Available at: http://www.fda.gov/cdrh/pdf7/K071729.pdf. Accessed January 25, 2008.
17. Shaffer DR, Leversha MA, Danila DC, et al. Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer. Clin Cancer Res 2007;13:2023-2029 (Pubitemid 46649868)
18. de Bono JS, Scher HI, Montgomery RB, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 2008;14:6302-6309
19. Scher HI, Eisenberger M, D'Amico AV, et al. Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 2004;22:537-556 (Pubitemid 41079783)
20. Bottomley A, Coens C, Efficace F, et al. Symptoms and patient-reported well-being: do they predict survival in malignant pleural mesothelioma? A prognostic factor analysis of EORTC-NCIC 08983: randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma. J Clin Oncol 2007;25:5770-5776
21. Sauerbrei W, Schumacher M. A bootstrap resampling procedure for model building: application to the Cox regression model. Stat Med 1992;11:2093-2109 (Pubitemid 23066842)
22. Danila DC, Heller G, Gignac GA, et al. Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res 2007;13:7053-7058 (Pubitemid 350276887)
23. Mao X, Shaw G, James SY, et al. Detection of TMPRSS2:ERG fusion gene in circulating prostate cancer cells. Asian J Androl 2008;10:467-473 (Pubitemid 351596036)